TCGA-A8-A0AB-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.410
- G2M_CHECKPOINT+0.370
- E2F_TARGETS+0.360
- MITOTIC_SPINDLE+0.350
- MYC_TARGETS_V1+0.310
- PROTEIN_SECRETION+0.310
- UV_RESPONSE_DN+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.150
- TGF_BETA_SIGNALING+0.110
- DNA_REPAIR+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.760
- INTERFERON_GAMMA_RESPONSE-0.690
- ALLOGRAFT_REJECTION-0.630
- INFLAMMATORY_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.480
- TNFA_SIGNALING_VIA_NFKB-0.470
- COMPLEMENT-0.440
- HEDGEHOG_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.390
- IL2_STAT5_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.908 |
| 2 | SRR8613736 | — | E | 0.895 |
| 3 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.894 |
| 4 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.884 |
| 5 | SJEPD030795_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.876 |
| 6 | SRR8943005 | — | — | 0.871 |
| 7 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.868 |
| 8 | SRR13780267 | — | cohortMD1 | 0.867 |
| 9 | TCGA-AR-A2LK-01A-11R-A180-07 | — | B | 0.859 |
| 10 | MBCProject_6127_T1_RNA | — | B | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |